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Abstract: The phosphoryl-transfer mechanism of shikimate kinase 
from Mycobacterium tuberculosis and Helicobacter pylori, an 




P NMR spectroscopy. Metaphosphoric acid proved to be a 
good mimetic of the metaphosphate intermediate in the ready and 
rapid evaluation by NMR of a dissociative mechanism. The required 
closed form of the active site for catalysis was achieved by the use 
of ADP (product) or two synthetic ADP analogues (AMPNP, 
AMPCP). The Molecular Dynamics simulation studies reported here 
also revealed that the essential arginine (Arg116/Arg117 in H. pylori 
and M. tuberculosis, respectively), which activates the γ-phosphate 
group of ATP for catalysis and triggers the release of the product for 
turnover, would also be involved in the stabilization of the 
metaphosphate intermediate during catalysis. We believe that the 
studies reported here would be helpful for the future structure-based 
design of inhibitors of this attractive target. The reported approach 
would also be useful to study the possible dissociative mechanism of 
other kinase enzymes. 
Introduction 
Phosphoryl-transfer reactions are amongst the most 
fundamental processes in biological systems. These reactions 
are crucial in the biosynthesis and replication of nucleic acids, 
the synthesis and assembly of key metabolites in a large variety 
of metabolic pathways and in energy and signal transduction, 
amongst others [1-7]. This type of reaction can proceed by three 
mechanistically different nucleophilic substitution pathways: (A) 
dissociative, in which a trigonal metaphosphate intermediate is 
formed first by cleavage of the OP bond in the donor, followed 
by subsequent nucleophilic attack of the acceptor; (B) 
associative, in which the nucleophile adds to the donor first with 
the formation of a pentavalent phosphorane intermediate, and 
then the leaving group is released; and (C) concerted, which 
proceeds through a single transition state with simultaneous 
cleavage and formation of two single bonds through a 
pentavalent transition state as in SN2 reactions (Scheme 1) [4,5]. 
These pathways differ in the timing of the cleavage of the 
phosphorus-leaving group bond and the formation of the 
phosphorus-nucleophile bond. The concerted process is a one-
step process with no intermediate. In contrast, associative and 
dissociative mechanisms are two-step processes that do involve 
an intermediate, although there are quite different (trigonal or 
trigonal bipyramid, respectively). Moreover, in the dissociative 
process, the acceptor is not involved in the intermediate. 
Examples of the three possible mechanisms have been 
described, although the reasons for the selection of a particular 
pathway for a given kinase are still unclear [8-13].  
Considering that many drugs that are highly successful in 
human clinical use mimic a transition state of a recognized 
target enzyme, a detailed knowledge of the catalytic mechanism 
of a chosen enzyme can be valuable for the rational design of 
mimetics (inhibitors) that can be used as drugs. Examples of 
drugs that are transition-state analogues include oseltamivir, a 
neuraminidase inhibitor in the treatment of the influenza virus, 
and saquinavir, an HIV protease inhibitor used in the treatment 
of AIDS. Structural studies have contributed greatly to this issue 
with the resolution of crystal structures of diverse kinases in 
complex with transition state analogues, reaction intermediates 
or metal fluoride complexes (e.g., AlF3 and BeF3
–) [8-11,14-15]. 
However, these techniques require large quantities of protein, 
they are time-consuming and, in many cases, it is difficult to find 
crystallization conditions to obtain crystals that provide good 
diffraction data. Phosphoryl-transfer reactions have also been 
studied by hybrid QM/MM calculations and this approach allows 
the study of bond making and breaking in a dynamic context that 
allows the reorganization of active site residues, substrate, and 
water molecules during the whole reaction coordinate [16-18]. 
However, due to the very demanding computational cost, the 
application of QM is still limited to a relatively small number of 
atoms, which is an issue for large active sites  particularly when 
the highest levels of theory are employed. We report here NMR 
studies that allowed the ready and rapid determination of the 
phosphoryl-transfer mechanism of a recognized attractive target 
for antibiotic drug discovery, namely shikimate kinase [19]. 
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Scheme 1. Phosphoryl-transfer reaction mechanisms. 
Shikimate kinase (SK, EC 2.7.1.71, aroK gene), the fifth enzyme 
of the shikimic acid pathway, catalyses the stereospecific 
phosphorylation of the C3 hydroxyl group of shikimic acid (1) by 
transferring the γ-phosphate group of ATP to the hydroxyl group 
to provide shikimate 3-phosphate (2) and ADP (Figure 1). SK is 
essential in several relevant pathogenic bacteria such as 
Mycobacterium tuberculosis, which is responsible for 
tuberculosis, Helicobacter pylori, which is the causative agent of 
gastric and duodenal ulcers and has also been classified as a 
type I carcinogen, and Pseudomonas aeruginosa, which is one 
of the most common pathogens in healthcare-associated 
infections and represents 13% of multidrug-resistant strains to 
nearly all antibiotics. SK has three domains (Figure 1): (1) the 
CORE domain that contains five stranded parallel -sheets and 
the P-loop, which forms the binding site for ATP and ADP; (2) 
the LID domain, which has an essential arginine for the binding 
of ATP (Arg116/Arg117 in H. pylori and M. tuberculosis, 
respectively); and (3) the substrate binding (SB) domain, which 
is responsible for the recognition and binding of shikimic acid (1). 
Structural and Molecular Dynamics (MD) simulation studies 
revealed that SK is exquisitely designed to recognize the 
unfavourable conformation of shikimic acid (1), which has a 
diaxial disposition of the C4 and C5 hydroxyl groups [20-22]. In 
this arrangement, the enzyme enables a selective 
phosphorylation of the C3 hydroxyl group in 1, which is arranged 
in an equatorial disposition. MD simulation studies also revealed 
that there are three key structural factors for catalysis: (1) a 
closed form of the LID domain to allow activation of the γ-
phosphate of ATP by the guanidinium group of the essential 
arginine (Arg116/Arg117 in H. pylori and M. tuberculosis, 
respectively); (2) a closed form of the SB domain in order to 
bring the substrates together for the phosphoryl-transfer reaction 
and to isolate the substrate within an apolar cavity, which is 
controlled mainly by two phenylalanine residues; and (3) a 
flexible LID and SB domain for product release, which is 
triggered by the essential arginine [14]. 
 
Figure 1. Enzymatic conversion of shikimic acid (1) to shikimate-3-phosphate 
(2) catalyzed by SK and its Michaelis complex. The three domains of H. pylori 
SK enzyme are shown: CORE (purple), LID (red) and SB (yellow). 






Given the important features of the SK enzyme, we recently 
became interested in the possible development of new 
antimicrobials that function by inhibition of this enzyme. To this 
end, the knowledge of the catalytic mechanism of this enzyme 
will be helpful for the mechanism- and structure-based design of 
inhibitors. We report here NMR studies that allowed the 
determination of the phosphoryl-transfer mechanism of the SK 
enzyme. Molecular Dynamics (MD) simulation studies with the M. 
tuberculosis and H. pylori SK enzymes were also carried out to 
gain a better understanding of the dynamic behaviour of the 
enzyme Michaelis complex and the stability of the proposed 
metaphosphate intermediate. We believe that the approach 
described here would also be useful for the evaluation of 
possible dissociative phosphoryl-transfer mechanisms of other 
kinase enzymes. 
Results and Discussion 
Based on the results of structural studies, it was suggested that 
Asp33/Asp34 (in H. pylori and M. tuberculosis, respectively) 
would act as a general base to deprotonate the C3 hydroxyl 
group in 1 for nucleophilic attack [21]. More importantly, it was 
proposed the phosphoryl-transfer reaction catalysed by SK 
proceeds through an associative mechanism with consequent 
generation of a pentacovalent phosphorane intermediate 
(Scheme 1B) [21]. As a consequence, both substrates would be 
involved in the reaction intermediate. However, MD simulation 
studies carried out with the SK Michaelis complex (SK/ATP/1) 
from Mycobacterium tuberculosis (Mt-SK) and Helicobacter 
pylori (Hp-SK) showed that in both cases the distance between 
the γ-phosphate of ATP and the oxygen atom of the C3 hydroxyl 
group of 1 is over 5 Å during most of the simulation (Figure 2 
and S1). It is important to highlight that single OP bonds are 
typically 1.6 Å. 
These Michaelis complexes were prepared using the enzyme 
geometries found in the crystal structures of Mt-SK (PDB code 
2IYQ [21]) and Hp-SK (PDB code 3MUF [20]) in complex with 
ADP and shikimic acid (1) or shikimate-3-phosphate (2), 
respectively, after manual replacement of the corresponding 
enzyme products by their substrates. The monomer of each SK 
in aqueous solution obtained using the molecular mechanics 
force field AMBER was employed [23]. These MD simulation 
studies revealed that both substrates seem to be quite far away 
for an associative or concerted mechanism, in which both donor 
and acceptor would be linked via a phosphorus atom, and the 
dissociative mechanism appears to be plausible. If the 
conversion of shikimic acid (1) into shikimate 3-phosphate (2) 
would take place by a dissociative mechanism, a 
metaphosphate intermediate that would be recognized by the 
enzyme would be generated and no covalent linkage between 
ATP and 1 would be required. In an effort to evaluate this 
hypothesis, we explored the possible conversion of 1 into 2 
catalysed by Hp-SK and Mt-SK in the absence of ATP and by 
external addition of metaphosphoric acid as a mimetic of the 
metaphosphate intermediate. The possible formation of 2 was 
followed by 1D 1H and 31P NMR spectroscopy. 
 
Figure 2. Relative distance between substrates in Michaelis complexes. 
Variation of the distance between the phosphorus atom of ATP γ-phosphate 
and the C3 oxygen atom of 1 during 32 ns of MD simulation of the M. 
tuberculosis (green) and H. pylori (red) SK/ATP/1 Michaelis complexes. 
The H. pylori enzyme used in these studies was expressed and 
produced using genomic DNA from an isolated clinical strain, 
courtesy of Guadalajara Hospital (Guadalajara, Spain). Mt-SK 
was produced and purified as described previously [24]. ADP 
was used in these experiments on considering previously 
reported circular dichroism [25], fluorescence [26] and structural 
[20,24] studies, which suggested that the ATP binding induces a 
large movement of the LID domain over the active site to bring 
two key arginines into close contact with the ATP and that a 
closed active site is required for catalysis [22]. Specifically, this 
process involved the conserved residues Arg107/Arg110 and 
the essential residues Arg116/Arg117 in H. pylori and M. 
tuberculosis, respectively. In this arrangement, the appropriate 
disposition of ATP in the active site, which is controlled by a 
cation-π interaction with Arg107/Arg110, and the activation of 
the γ-phosphate of ATP by the guanidinium group of the 
essential arginine would occur. As shown in Figure 3, 
comparison of the crystal structures of Mt-SK/ADP/1 (PDB 2IYQ, 
[21]) and Mt-SK/1 (2IYS, [21]) complexes shows that in the 
absence of ADP the LID is in the open conformation and the 
essential Arg117 is located over 20 Å away from the active site. 
The Mt-SK/ADP/1 crystal structure (PDB 2IYQ) also revealed 
that a closed conformation of the active site is achieved in the 
presence of ADP. More importantly, superposition of the Mt-SK 
Michaelis complex and the Mt-SK/ADP/1 crystal structure 
highlights how the essential Arg117 is pointing towards the 
active site. Therefore, we consider that by using ADP (product) 
in the NMR experiments a similar conformation of the active site 
for catalysis would also be generated.  
The 1D 1H and 31P NMR monitoring of the formation of shikimate 
3-phosphate (2) from shikimic acid (1) catalysed by Hp-SK in the 
presence of ADP after the addition of metaphosphoric acid, a 
polymeric form of HOPO2, is shown in Figure 4. The natural 
enzymatic conversion of shikimic acid (1) and ATP catalysed by 
Mt-SK to give shikimate 3-phosphate (2) and ADP was also 
studied by NMR spectroscopy (Figure S2). The latter 






experiments were carried out using very small amounts of Mt-SK, 
which also has a high Km, in order to follow easily the enzymatic 
conversion. As it is shown in Figure S2, conversion of ATP into 
ADP was not observed in the absence of 1 but it is a very fast 
process after the addition of 1. Control experiments showed that 
the reaction did not occur in the absence of ADP (Figure S3) or 
in the absence of enzyme (Figure S4). In addition, the use of 
other commercially available mimetics of the metaphosphate 
intermediate such as barium or aluminium metaphosphate failed 
due to their lack of solubility under the reaction conditions. 
 
Figure 3. Superposition of the crystal structures of Mt-SK/ADP/1 (PDB 
2IYQ,[20]) and Mt-SK/1 (2IYS, [20]) complexes and Mt-SK Michaelis complex. 
Note how in the absence of ADP or ATP the LID is in the open conformation 
and the essential Arg117 is located over 20 Å away from the active site. 
1D 1H and 31P NMR spectra of a mixture of 1 and ADP in the 
presence of a catalytic amount of the Hp-SK enzyme were 
recorded before (Figure 4A) and after the addition of 
metaphosphoric acid (Figures 4B–E). After 10 minutes of 
incubation (Figure 3B), the formation of 2 could already be 
detected and it was clearly observed after 6 hours (Figure 4C). 
The most relevant signals in the 1D 1H and 31P NMR spectra that 
reveal the formation of 2 are: (a) one singlet (δH 6.39 ppm) and 
two multiplets (δH 3.98 ppm and 3.76 ppm) in the 
1H NMR 
spectra corresponding to H2, H5 and H4 of 2, respectively; (b) 
one singlet (δP 0.6 ppm) in the 
31P NMR spectra corresponding 
to the phosphate group of 2. Similar results were obtained on 
using the Mt-SK enzyme (Figure S5). We assume that the 
singlet observed in the 31P NMR spectra at δP 0.1 ppm (Figure 
4B) after the addition of metaphosphoric acid corresponds to 
some hydrolysis of this acid (phosphoric acid) and that it is also 
observed in the control experiments carried out in the absence 
of enzyme or ADP (Figures S4 and S3, respectively). However, 
control experiments on the stability of metaphosphoric acid 
showed that this compound is quite stable under the assay 
conditions as significant changes were not observed in the 31P 
NMR monitoring and it can therefore be used for the reported 
NMR studies (Figure S6). 
Comparison of the experiments carried out in the presence of 
ADP and with the external addition of metaphosphoric acid 
(Figure 3) with the 1H and 31P NMR monitoring of the natural 
formation of shikimate 3-phosphate (2) from shikimic acid (1) 
and ATP catalysed by Mt-SK (Figure S2) revealed that the 
stereospecific phosphorylation of the C3 hydroxyl group of 1 
takes place in the reported experiments as in the natural 
enzymatic conversion. The findings that: (1) no reaction is 
observed in the absence of enzyme, (2) a closed conformation 
of the active site is required for reaction, i.e. with the essential 
arginine in close contact with the substrates/products, which is 
achieved by using ADP and (3) nonspecific phosphorylation 
reactions of the other hydroxyl groups were detected, all suggest 
that the enzyme seems to be able to recognize metaphosphoric 
acid, more likely the terminal part of this polymer, in a similar 
way to the reaction intermediate to subsequently undergo a 
nucleophilic attack by the C3 hydroxyl group in 1. These results 
also revealed that no covalent linkage between donor and 
acceptor seems to be required for enzymatic catalysis since 
shikimic acid (1) can be converted into shikimate 3-phosphate 
(2) by external addition of a mimetic of the metaphosphate 
intermediate (second step of dissociative process). 
In order to prove that the presence of ADP is required to achieve 
the appropriate arrangement for catalysis but that it does not 
participate in the reaction, two synthetic analogues of ADP, 
namely AMPNP and AMPCP, were also employed (Figures 5 
and 6). Adenosine-5’-[(α,β)-imido]diphosphate (AMPNP) and 
adenosine-5’-[(α,β)-methyleno]diphosphate (AMPCP), are ADP 
analogues in which the β-phosphate is replaced by a 
imidophosphate and a methylenophosphate derivatives, 
respectively. As it is shown in Figure 5, the NMR results indicate 
that Hp-SK also catalyses the stereospecific phosphorylation of 
the C3 hydroxyl group of 1 by addition of metaphosphoric acid in 
the presence of AMPNP. The latter experiments also highlight 
the required closed form of the LID for catalysis. Remarkably, 
this process was much faster than when using ADP. Thus, to 
achieve ~50% conversion, incubation for 24 hours is required 
when using ADP vs only 2 hours for AMPNP. In contrast, the 
experiments carried out using AMPCP showed that the 
conversion of 1 into 2 is much slower (Figure 6). In fact, the 
enzymatic reaction required the use of much large quantities of 
metaphosphoric acid and under these conditions only ~20% 
conversion was obtained. 
Considering that the differences observed on using ADP, 
AMPNP and AMPCP would be due to some differences in 
achieving a closed arrangement of the active site, MD simulation 
studies were performed. These studies were also carried out in 
aqueous solution using the molecular mechanics force field 
AMBER. The three possible Hp-SK/L/1 complexes were then 
subjected to 50 ns of dynamic simulation (L = AMPNP, AMPCP 
or ADP). As it is shown in Figure 7, AMPNP proved to be the 
ligand that provides the most efficient closed form of the active 
site with the essential arginine side chain in close contact with 
the phosphate groups of the ligand and with the shikimic acid (1) 
anchored in the SB domain in the appropriate conformation for 
reaction [22]. Significant changes were not observed during the 
whole simulation and a tidy closed active site seems to be 






achieved (Figure 7A). A similar situation was obtained with the 
Hp-SK/ADP/1 complex. In contrast, for the Hp-SK/AMPCP/1 
complex, a less stable closed arrangement of the active site was 
obtained (Figure 7B). 
 
 




P NMR monitoring of the enzymatic conversion of shikimic acid (1) to shikimate 3-phosphate (2) catalysed by Hp-SK in the presence of 




P NMR spectra: (A) of 1, ADP and Hp-SK under the assay conditions. (B) 10 min after the addition of metaphosphoric 
acid (18 mM) to (A). (C) after 6 h incubation. (D) after 24 h incubation. (E) after 96 h incubation. All experiments were recorded at 500 MHz (
1
H) or 202 MHz (
31
P) 
and 298 K using ADP (4.5 mM), 1 (6.4 mM) and a catalytic amount of Hp-SK (10 units) in Tris-d11.DCl (100 mM, pD 7.7), KCl (100 mM) and MgCl2 (5 mM). Only 
relevant regions of the 
1
H NMR spectra are shown for clarity. The most relevant signals that reveal the formation of 2 are marked with an arrow (C). The observed 
31
P signals in the ADP solution, which corresponds to phosphate (Pi), β-phosphate of ADP (Pb) and -phosphate of ADP (Pa), are labeled. 
Our simulation studies inidicate that significant motion in the 
substrate covering-loop, the essential arginine and SB domain 
would occur. As a consequence, the substrate seems to be less 
anchored in the SB domain for the enzymatic reaction to occur. 
The binding free energy of shikimic acid (1) in the three Hp-
SK/L/1 complexes was calculated using the MM/PBSA [27] 
approach in explicit water (GB) as implemented in AMBER. The 
results suggest that 1 has about a 6-fold higher affinity for the 
Hp-SK/ADP and Hp-SK/AMPNP complexes than for the Hp-
SK/AMPCP one. We consider that this motion might be 
responsible for the experimentally observed lower efficiency of 
the enzymatic conversion when AMPCP is used. 
 












P NMR monitoring of the enzymatic conversion of shikimic acid (1) to shikimate 3-phosphate (2) catalysed by Hp-SK in the presence of 




P NMR spectra: (A) 1, AMPNP and Hp-SK under the assay conditions. (B) after addition to (A) of metaphosphoric 
acid (18 mM). (C) after 20 min incubation. (D) after 1 h incubation. (E) after 2 h incubation. (F) after 5 h incubation. (G) after 24 h incubation. All experiments were 
recorded at 500 MHz (
1
H) or 202 MHz (
31
P) and 298 K using shikimic acid (3.2 mM), AMPNP (1.8 mM) and a catalytic amount of Hp-SK (10 units) in Tris-d11.DCl 
(100 mM pD 7.7), KCl (100 mM) and MgCl2 (5 mM). Only relevant regions of the 
1
H NMR spectra are shown for clarity. The most relevant signals that reveal the 




H signals shown in panel A corresponding to relevant peaks of 1 and AMPNP are labelled. Pb, Pa and 
Pi correspond to β- and -phosphate of AMPNP and phosphate, respectively. Ad = adenosine moiety. 












P NMR monitoring of the enzymatic conversion of shikimic acid (1) to shikimate 3-phosphate (2) catalysed by Hp-SK in the presence of 




P NMR spectra: (A) 1, AMPCP and Hp-SK under the assay conditions. (B) after addition to (A) of metaphosphoric 
acid (36 mM). (C) after 18 h incubation. (D) after addition to (C) of metaphosphoric acid (total concentration 54 mM) and 33 h incubation. All experiments were 
recorded at 500 MHz (
1
H) or 202 MHz (
31
P) and 298 K using shikimic acid (3.2 mM), AMPCP (4.5 mM) and a catalytic amount of Hp-SK (10 units) in Tris-d11.DCl 
(100 mM pD 7.7), KCl (100 mM) and MgCl2 (5 mM). Only relevant regions of the 
1
H NMR spectra are shown for clarity. The most relevant signals that reveal the 




H signals shown in panel A corresponding to relevant peaks of 1 and AMPCP are labelled. Pb, Pa and 
Pi correspond to β- and -phosphate of AMPCP and phosphate, respectively. Ad = adenosine moiety. 
In an effort to gain an insight into the stability and the binding 
mode of the proposed metaphosphate intermediate in the active 
site of Hp-SK, MD simulation studies were performed. The Hp-
SK/ADP/PO3/1 complex was then subjected to 50 ns of dynamic 
simulation. As shown in Figure 8, the metaphosphate 
intermediate remains trapped between the ADP and the shikimic 
acid (1) during the simulation, mainly due to the strong 
electrostatic interactions with the guanidinium group of the 
essential Arg116, the side chain of Lys14 and Mg2+. This 
process can be clearly visualized by analyzing the variation of 
the distances involving the O1 oxygen atom of PO3
– and the NZ 
atom of Lys14 (red), the O2 oxygen atom of PO3
– and Mg2+ 
(purple), the O3 oxygen atom of PO3
– and the NH2 and NE 
atoms of the essential Arg116 (green and blue, respectively) 
during the whole simulation (Figure 8C). It has been previously 
suggested that Arg116/Arg117 might also act by activating the γ-
phosphate group of ATP for catalysis and also trigger the 
release of the product from the active site [22]. These studies 
revealed that Arg116 might also act by activating and positioning 
the metaphosphate intermediate for subsequent nucleophilic 
attack by the C3 hydroxyl group in 1. Moreover, considering that 
the conversion of ATP to ADP is exothermic (–7.3 kcal/mol), one 
would expect that the rate-limiting step of the reaction catalysed 
by SK would be the nucleophilic attack by the C3 hydroxyl group 
to the metaphosphate intermediate to afford a tetrahedral 
transition state. Potential inhibitors that target the SK enzyme 
might be mimetics of this tetrahedral species. 
A dissociative mechanism is supported by the findings: (1) the 
distance observed between the phosphorus atom of ATP γ-
phosphate and the C3 hydroxyl atom of 1 during 32 ns of 
simulation of both SK/ATP/1 Michaelis complexes is over 5 Å 
during most of the simulation. Therefore, both substrates seem 
to be quite far away to form a pentavalent phosphorane 
intermediate in which the two substrates are linked through a 






phosphorus atom with distances between O and P atoms close 
to a single OP bond (1.6 Å); and (2) the results from our NMR 
studies showing that the enzyme seems to be able to recognize 
metaphosphoric acid to perform the stereospecific 
phosphorylation of the C3 hydroxyl group in 1, as occurs on 
using ATP as the phosphorus source and when a closed form of 
the active site is achieved either using ADP, AMPNP or AMPCP. 
Hybrid QM/MM calculations are required to gain further insights 
into the catalytic mechanism in atomic detail and this study is 
currently in progress in our laboratories. 
Conclusions 
The results reported here indicate that the reaction catalysed by 
SK would involve a dissociative phosphoryl-transfer mechanism 
via a metaphosphate intermediate. Commercially available 
metaphosphoric acid proved to be a good mimetic of the latter 
intermediate, the transformation of which by the enzyme can be 
easily followed by 1D 1H and 31P NMR spectroscopy. These 
experiments require the presence of ADP or a synthetic 
analogue of ADP, such as AMPNP or AMPCP in order to 
achieve a closed form of the LID with the guanidinium group of 
the essential arginine (Arg116/Arg117 in H. pylori and M. 
tuberculosis, respectively) in close contact with the substrates 
and products. Of the two synthetic analogues of ADP used in 
these studies, AMPNP proved to me more efficient than when 
using AMPCP. The results of the MD simulation studies 
suggested that AMPNP and ADP would provide a better 
disposition of shikimic acid in the active site for catalysis than 
AMPCP, which might account for their higher efficiency. The 
results of the simulation studies also suggest that the essential 
arginine would also be involved in the stabilization of the 
metaphosphate intermediate during the catalysis. We believe 
that the NMR studies reported here would be helpful for the 
future mechanism- and structure-based design of inhibitors of 
this attractive target for antibiotic drug discovery as well as for 
the ready and rapid evaluation of possible dissociative 
phosphoryl-transfer mechanisms of other kinase enzymes. 
 
 
Figure 7. Comparison of several snapshots of the position of shikimic acid (1), ADP and the two ADP analogues in the Hp-SK/AMPNP/1 (A), Hp-SK/AMPCP/1 
(B,D) Hp-SK/ADP/1 (C) complexes during 50 ns of MD simulations. Note how in the Hp-SK/AMPNP/1 and Hp-SK/ADP/1 complexes the position of the essential 
arginine side chain and the substrate covering-loop remain stable during simulation. In contrast, for the Hp-SK/AMPCP/1, a less stable closed arrangement of the 
active site is obtained. Only relevant side chain residues are shown and labelled. 
 







Figure 8. MD simulation studies of Hp-SK/ADP/PO3/1 complex. (A) Comparison of several snapshots of the position of ADP, the metaphosphate intermediate and 
the substrate in the Hp-SK/ADP/PO3/1 complex during 50 ns of MD simulations. Note how the metaphosphate intermediate remains trapped between the ADP 
and the substrate during the simulation, mainly due to the strong electrostatic interaction with the guanidinium group of the essential Arg116. (B) Detailed view of 
the relevant binding interactions of the metaphosphate intermediate in the active site of Hp-SK after 10 ns of MD simulation. (C) Variation of the distance between 
the O1 oxygen atom of PO3
–




 (purple), the O3 oxygen atom of PO3
–
 and the NH2 and NE 
atoms of the essential Arg116 (green and blue, respectively) during 50 ns of MD simulation of the two Hp-SK/ADP/PO3/1 complexes. Relevant side-chain 
residues are shown and labelled. 
Experimental Section 
Helicobacter pylori SK cloning, expression and purification. The 
aroK gene, which encodes Hp-SK, was PCR-amplified using genomic 
DNA from an isolated clinical strain, courtesy of the Guadalajara Hospital 
(Guadalajara, Spain) as template with the Expand High Fidelity PCR 
System (Roche). H. pylori strain was cultured in Columbia agar plates in 
microaerobic conditions (GasPak™ EZ CampyPouch™ System, Becton 
and Dickinson). The forward primer included a recognition site for the 
restriction enzyme NdeI (5’-
CGCATCCATATGCAGCATTTAGTTTTAATCG-3’) and the reverse 
primer for the restriction enzyme BamHI (5’-
CGGGATCCTTATGCGATGAATTGTAGCAC-3’). The PCR-amplified 
fragment, corresponding to aroK gene, was digested with NdeI and 
BamHI and ligated to the expression vector pET3a previously digested 
with the same restriction enzymes. Comparison of the amino acid 
sequence in Hp-SK enzymes from AROK_HELPY, P56073 (strain ATCC 
700392/26695) with clinically isolated strain from Guadalajara Hospital 
(Spain) revealed that the latter strain has three changes, specifically V75I, 
M99I and T123A (Figure S7). A similar comparison with AROK_HELPJ, 
Q9ZMS3 (strain J99 / ATCC 700824) showed two changes, specifically 
M99I and T123A. 
The nucleotide sequence encoding the Hp-SK enzyme was subcloned 
into the Escherichia coli expression plasmid pET3a via 5/Nde1 and 
3/BamH1 sites. The resulting plasmid was designated pMUT319. E. coli 






strain BL21-AI was transformed with pMUT319 and transformants were 
selected at 37 oC on Luria Broth (LB) agar supplemented with 100 mg 
mL-1 ampicillin. Transformed cells were grown in drug supplemented LB 
at 25 oC to an attenuance of 0.8 at 550 nm, at which time the 
temperature was reduced to 15 oC. The culture medium was then made 
0.2% (w/v) with arabinose and the incubation continued at 15 oC for a 
further 15 h. Cells were harvested by centrifugation (4 oC, 10,000xg, 10 
min.) and stored at –20 oC until needed. 50g of cell paste was sonicated 
at 4 oC in 50 mM potassium phosphate buffer pH 7.2, 150 mM NaCl, 1 
mM DTT, 1 mM benzamidine (buffer 1). Insoluble material was removed 
at 4 oC by centrifugation at 21,860xg for 1 h. The clarified supernatant 
was then applied to a Q sepharose column (5×15 cm) equilibrated in 50 
mM potassium phosphate buffer pH 7.2, 150 mM NaCl, 1 mM DTT 
(buffer 2). The column flow through and a 1 L wash of buffer 2 were 
combined and made 35% saturated with ammonium sulfate. Precipitated 
material was removed at 4 oC by centrifugation at 13,690xg for 1 h. The 
supernatant was made 55% saturated with ammonium sulfate and the 
precipitated material recovered by centrifugation at 13,690xg for 1 h. The 
pellet was recovered, dissolved in 170 mL of 50 mM potassium 
phosphate buffer pH 7.2, 150 mM NaCl, 1mM DTT, 1.0 M ammonium 
sulfate (buffer 3) and loaded on to a phenyl Sepharose column (5×15 cm) 
equilibrated in buffer 3. Following a 1.0 L wash with buffer 3, the column 
was eluted with a 1 L ammonium sulfate gradient (1.0 M to 0.0 M in 
buffer 2) collecting 1 mL fractions. At the end of the gradient the column 
was washed with a further 500 mL of buffer 3 collecting 10 mL fractions. 
Hp-SK containing fractions were identified by SDS-PAGE (12% gel) and 
pooled appropriately. Hp-SK protein was then dialysed against 3×5 L 
changes of 25 mM potassium phosphate buffer pH 6.6, 150 mM NaCl, 1 
mM DTT (buffer 4) and loaded onto a hydroxyapatite column (5×7.5 cm) 
equilibrated in buffer 4. Following a 500 mL wash with buffer 4, the 
column was then eluted with a gradient of potassium phosphate buffer 
pH 6.6 (1 L, 25 to 400 mM) containing 150 mM NaCl and 1 mM DTT 
collecting 10 mL fractions. Hp-SK containing fractions were identified by 
SDS-PAGE (12% gel) and pooled appropriately. The pooled protein (100 
mL) was dialysed against 5 L buffer 2 yielding approximately 820 mg of 
Hp-SK at greater than 95% purity. 
Shikimate kinase assay. A concentrated solution of Hp-SK (7.4 mg mL-
1) in potassium phosphate buffer (50 mM, pH 7.2), DTT (1 mM) and NaCl 
(150 mM), which was stored at at 80 °C, was used. Shikimate kinase 
from M. tuberculosis (Mt-SK) was purified as described previously [24] 
and the concentrated solution (1.5 mg mL-1) was stored in potassium 
phosphate buffer (50 mM, pH 7.2), DTT (1 mM) and NaCl (150 mM) at 
80 °C. When required for assays aliquots of the enzyme stocks were 
diluted into buffer and stored on ice. Enzyme activity was measured by 
monitoring the decrease in absorbance at 340 nm in the UV spectrum 
due to the absorbance of NADH (ε/M-1 cm-1 6 200) in a coupled assay 
format wherein ADP formed after the formation of shikimate-3-phosphate 
(2) was detected using pyruvate kinase (PK) and lactate dehydrogenase 
(LDH). Oxidation of NADH to NAD during PK-LDH activity was monitored 
at 340 nm. Standard assay conditions for shikimate kinase were 100 mM 
Tris.HCl pH 7.7, 100 mM NaCl, 5 mM MgCl2, 2.5 mM ATP, 1 mM 
shikimic acid (1), 0.20 mM NADH, 2.8 units of PK-LDH and 0.03 unit of 
SK protein. One unit of enzyme is defined as the amount of enzyme 
required to convert 1 µmol of substrate to product in 1 min. Each assay 
was initiated by addition of shikimic acid (1). Solutions of ATP and NADH 
were calibrated by measuring the absorbance at 259 nm and 340 nm in 
the UV spectrum, respectively. Solutions of shikimic acid (1) were 
calibrated by equilibration with SK and measurement of the change in the 
UV absorbance at 340 nm due to the disappearance of NADH. The initial 
rates at fixed enzyme and substrate concentrations (0.2–5 Km) were 
measured. Kinetic constants were evaluated using the GraFit 5 program 
(Erithacus Software Ltd.). The determined kinetic parameters for Hp-SK 
and Mt-SK were Km (1) = 39  8 µM; kcat = 116  4 10
–3 s−1 and Km (1) = 
544  14 µM; kcat = 295  8 s
−1, respectively (Table S1). 
Molecular Dynamics Simulations. Ligand preparation. Ligand 
geometries were minimized using a restricted Hartree–Fock (RHF) 
method and a 6–31G(d) basis set, as implemented in the ab initio 
program Gaussian 09 [28]. Ligands were manually docked into the active 
site. The resulting wavefunctions were used to calculate electrostatic 
potential-derived (ESP) charges employing the restrained electrostatic 
potential (RESP) [23] methodology, as implemented in the assisted 
model building with energy refinement (AMBER) [29] suite of programs. 
The missing bonded and non-bonded parameters were assigned, by 
analogy or through interpolation, from those already present in the 
AMBER database (GAFF) [30]. 
Generation and minimization of the SK Michaelis complexes. b) Mt-SK 
model: simulations were carried out using the enzyme coordinates found 
in the crystal structure of Mt-SK in complex with ADP and shikimic acid 
(1) (PDB code 2IYQ [21]) and after manual replacement of ADP by ATP. 
b) Hp-SK model: These studies were carried out using the enzyme 
coordinates found in the crystal structure of Hp-SK/ADP/2 complex (PDB 
code 3MUF [20]) after manual replacement of both products by the 
substrates.  
Crystallographic water molecules were maintained in both complexes 
except for those coordinated with the -phosphate of ADP in PDB 2IYQ. 
For the two Michaelis complexes, the crystallographic water molecules 
coordinated with the γ-phosphate of ATP and Mg2+ in PDB 2IYW were 
also added. Protein N- and C-terminal groups were modified as N-acetyl 
and N-methyl amide derivatives, respectively. Computation of the 
protonation state of titratable groups at pH 7.0 were carried out using the 
H++ Web server [31]. Addition of hydrogen and molecular mechanics 
parameters from the ff03 and GAFF force fields, respectively, were 
assigned to the protein and the ligands using the LEaP module of 
AMBER 12 [32]. ATP, ADP and Mg2+ parameters used with the AMBER 
force field were included [33-35]. Energy minimization using the implicit 
solvent GB model was then carried out in stages, starting with ligand 
(1000 steps, half of them steepest descent, the other half conjugate 
gradient), protein side chains (1000 steps, idem) and finally the entire 
complex (1000 steps, idem). A positional restraint force constant of 50 
kcal mol-1 Å-2 was applied to those unminimized atoms in each step 
during all calculations. The complex was neutralized by addition of 
chloride ions and immersed in a truncated octahedron of 5300 TIP3P 
water molecules [36-38]. 
Simulations. MD simulations were performed using the sander module 
[39] from the AMBER 12 suite of programs. Periodic boundary conditions 
were applied, and electrostatic interactions were treated using the 
smooth particle mesh Ewald method (PME) [40] with a grid spacing of 1 
Å. The cutoff distance for the nonbonded interactions was 9 Å. The 
SHAKE algorithm [41] was applied to all bonds containing hydrogen, 
using a tolerance of 10–5 Å and an integration step of 2.0 fs. Minimization 
was carried out in three steps, starting with the octahedron water 
hydrogens, followed by solvent molecules and counterions, and finally 
the entire system. The minimized system was heated at 300 K (1 atm, 
200 ps, a positional restraint force constant of 50 kcal mol–1 Å–2). These 
initial harmonic restraints applied to all α carbons were gradually reduced 
from 5 to 1 mol–1 Å–2 (6 steps, 100 ps each), and the resulting systems 
were allowed to equilibrate further (100 ps). Unrestrained MD simulations 
were carried out for 32 ns. System coordinates were collected every 10 
ps for further analysis. Figures depicting structures were prepared using 
PYMOL [42]. 






NMR Experiments. All NMR experiments were performed on a Varian 
Inova 500 spectrometer at 500 MHz (1H) or 202 MHz (31P) and 298 K 
using shikimic acid (1) (6.4 mM), ADP sodium salt (4.5 mM), KCl (100 
mM) and MgCl2 (5 mM) in Tris-d11.DCl (100 mM, pD 7.7) and a catalytic 
amount of Hp-SK (10 units) or Mt-SK (3 units). The reaction was initiated 
by the addition of a solution of metaphosphoric acid (18 mM) to a solution 
of 1, ADP, KCl, MgCl2 in deuterated buffer. The stock samples of 1 (50 
mM), ADP (50 mM) and metaphosphoric acid (1 M) were prepared in 
deuterated buffer. The total volume of each NMR sample was 550 µL. 
Solvent suppression of the residual HDO peak was achieved by 
continuous low power presaturation pulse during the relaxation delay. 
NMR spectra were recorded prior and after the addition of 
metaphosphoric acid over 96 h period, unless is indicated. 
The NMR experiments carried with adenosine-5´-[(α,β)-
imido]diphosphate sodium salt (AMPNP) and adenosine-5´-[(α,β)- 
methyleno]diphosphate sodium salt (AMPCP), which were purchase from 
Jena Bioscience, were performed as those with ADP (see above). It was 
employed shikimic acid (1) (3.2 mM), AMPNP (1.8 mM), KCl (100 mM) 
and MgCl2 (5 mM) in Tris-d11.DCl (100 mM, pD 7.7), metaphosphoric 
acid (18 mM) and a catalytic amount of Hp-SK (10 units). For those 
experiments carried out with AMPCP (4.5 mM), a higher concentration of 
metaphosphoric acid (36 mM) was employed. After 18 h incubation, more 
metaphosphoric acid was added (10 µL of 1 M stock) to achieve a total 
concentration of 54 mM. For those control experiments carried out in the 
absence of ADP or the enzyme, the corresponding amount was replaced 
by deuterated buffer.  
The NMR monitoring of the enzymatic conversion of shikimic acid (1) and 
ATP to provide shikimate 3-phosphate (2) and ADP was carried out using 
ATP magnesium salt (4.5 mM), shikimic acid (1) (6.4 mM), KCl (100 mM) 
and MgCl2 (5 mM) in Tris-d11.DCl (100 mM pD 7.7). NMR spectra were 
recorded prior and after the addition of 1 to detect possible changes in 
the ATP. The reaction was then initiated with the addition of a catalytic 
amount of Mt-SK (0.3 units). NMR spectra were immediately recorded 
after the addition of the enzyme and over 18 h period. 
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NMR approach to study the possible 
dissociative phosphoryl-transfer 
mechanism of shikimate kinase is 
reported. Metaphosphoric acid proved 
to be a good mimetic of the reaction 
intermediate. A closed conformation of 
the active site, which is required for 
catalysis, was achieved by using ADP 
or synthetic analogues of ADP 
(AMPNP, AMPCP). 
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